Exact Sciences Corp
Company Profile
Business description
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Contact
5505 Endeavor Lane
MadisonWI53719
USAT: +1 608 284-5700
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2024
Employees
6,600
Exact Sciences Corp News & Analysis
etfs
ARK Innovation ETF has likely been a disappointment for most investors
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,645.30 | 78.30 | 0.91% |
| CAC 40 | 7,213.32 | 14.87 | 0.21% |
| DAX 40 | 19,146.17 | 141.39 | 0.74% |
| Dow JONES (US) | 43,870.35 | 461.88 | 1.06% |
| FTSE 100 | 8,149.27 | 64.20 | 0.79% |
| HKSE | 19,343.91 | 257.20 | -1.31% |
| NASDAQ | 18,972.42 | 6.28 | 0.03% |
| Nikkei 225 | 38,365.24 | 339.07 | 0.89% |
| NZX 50 Index | 13,041.90 | 276.66 | 2.17% |
| S&P 500 | 5,948.71 | 31.60 | 0.53% |
| S&P/ASX 200 | 8,406.00 | 83.00 | 1.00% |
| SSE Composite Index | 3,336.93 | 33.47 | -0.99% |